Tatva Chintan Pharma Chem Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/es26upotkhwfi0e4pufbecjj.pdf

Key Takeaways


SDA: The Near-Term Earnings Engine

Chintan Shah: "So, we don't want this. That is how we ended up in SDA. And I think we are there since 2015. So we have completed 10 years in this category, and we have not seen one single competition in India coming in."

Margins & Plant Occupancy

Chintan Shah: "I see that over next 2 quarters, eventually plant is going to be fully occupied and that is when we will actually strike the right EBITDA margins, which I have been always claiming to be in the range of 20% to 22%."

Agro & Pharma: The Volume Ramp Begins

Chintan Shah: "So we expect a phenomenal year in 2027, calendar year is going to be awesome where probably the new capacities will also be fully optimized."

Electrolyte Salts & Energy Storage


Semiconductor Chemicals: The Long-Gestation Bet

Chintan Shah: "The more I know and understand by meeting with these customers, it is really a scary affair."

New Capacity & Infrastructure


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA marginsAchieve 20% to 22% rangeNext 2 quarters
New plant blockAvailable for commercial productionJanuary 2026
Pharma commercialization3 products commercialized; DMF filing by JuneDecember 2025 to H2 2026
Agro intermediate volume scalingRealistic volumes from customer beginJune 2026 onwards
Semiconductor commercial batchesDeliver 3 commercial-scale batchesQ4 FY26
Electrolyte salts revenue₹20–25 crore-plusFY27
Semiconductor real commercializationMeaningful business beginsEnd of 2027 / early 2028
Jolva plant ground-breakingConstruction start for large agro intermediate plantJanuary–February 2026
New electrolyte productOpportunity exists only if US tariff drops to 25%Contingent on policy

Key Metrics

MetricQ2 FY26
Operating revenue₹123.5 cr, +48% YoY and +6% QoQ
EBITDA₹22.2 cr, +298% YoY and +28% QoQ
Phase Transfer Catalysts revenue₹29.3 cr, +7% YoY and +1% QoQ
Electrolyte Salts revenue₹1.2 cr, -5% YoY and +47% QoQ
Pharma, Agro and Specialty Chemicals revenue₹32.4 cr, +19% YoY and -31% QoQ
Structure Directing Agents revenue₹59.3 cr, +119% YoY and +51% QoQ
SDA plant utilization~50%
Other plant utilization~80%
EBITDA margin target20% to 22%, expected over next 2 quarters
Electrolyte Salts full-year revenue guidance~₹15 cr (FY26)
Pharma and agro molecules full-scale revenue potential₹300 cr to ₹350 cr (ballpark, 7–8 molecules)
Agro products volume growth outlook~1.5x in FY27, then another ~1.5x in FY28
Capital employed (H1 FY26)~₹680 cr, comprising net block of ₹480 cr and working capital of ~₹200 cr
EBIT (H1 FY26)₹25 cr, implying ~4% pre-tax ROCE
Plant revenue capacity₹800 cr to ₹850 cr
EBITDA target from existing plantup to ₹175 cr
Import content in raw materials40% to 45%